头孢吡肟与死亡率：一个实际问题？
Cefepime and mortality: a real issue?
作者信息
Mebis Jeroen, Goossens Herman, Berneman Zwi Nisan
机构信息
Department of Medical Oncology, Virga Jesse Hospital, Hasselt, Belgium.
出版信息
Scand J Infect Dis. 2010 Jul;42(6-7):545-8. doi: 10.3109/00365540903555349.
The fourth-generation cephalosporin, cefepime, has an antimicrobial spectrum that makes it a valuable antibiotic for empirical treatment of neutropenic fever. Randomized trials have proven the efficacy and safety of cefepime in neutropenic fever. However, 2 recent meta-analyses have shown an increased all-cause mortality for cefepime. Since then, many clinicians have been left in doubt about the use of cefepime for this indication. In this paper, we put in perspective some of the methodological and clinical issues and call for further clinical analyses.
第四代头孢菌素头孢吡肟具有抗菌谱，使其成为经验性治疗中性粒细胞减少性发热的一种有价值的抗生素。随机试验已证明头孢吡肟治疗中性粒细胞减少性发热的有效性和安全性。然而，最近的两项荟萃分析显示，使用头孢吡肟会增加全因死亡率。自那以后，许多临床医生对将头孢吡肟用于这一适应症产生了怀疑。在本文中，我们对一些方法学和临床问题进行了分析，并呼吁进行进一步的临床分析。
Zotero 插件